Cel­gene-part­nered An­ten­gene preps new Chi­na deals as $21M round lands

Just a few months af­ter ink­ing a deal to de­vel­op one of Cel­gene’s ex­per­i­men­tal can­cer drugs for the Chi­nese mar­ket, An­ten­gene has un­veiled a $21 mil­lion A round to help pay for the work.

An­ten­gene bears some clas­sic marks of a Chi­na-based start­up. Its CEO is Jay Mei, who held a se­nior de­vel­op­ment po­si­tion with Cel­gene and spear­head­ed Revlim­id’s ap­proval in Chi­na. Cel­gene, mean­while, took an eq­ui­ty stake in the com­pa­ny as it passed over Asian rights to its TORC1/2 in­hibitor CC-223.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER